Coenzyme Q10 – A new player in the treatment of heart failure?

Pharmacological Reports

Volumn 68, Issue 5, 2016, Pages 1015-1019

  Jankowski, Jerzy ^a   Korzeniowska, Katarzyna ^a   Cieślewicz, Artur ^a   Jabłecka, Anna ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Coenzyme q10; Heart failure; Supplementation

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO; UBIDECARENONE; UBIQUINONE;

CARDIOVASCULAR MORTALITY; CLINICAL TRIAL (TOPIC); DIET SUPPLEMENTATION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FORMULATION; HEART FAILURE; HEART FUNCTION; HEMODYNAMIC PARAMETERS; HUMAN; HYDROPHOBICITY; LIPID PEROXIDATION; MORBIDITY; OXIDATIVE STRESS; PHARMACODYNAMICS; PHARMACOKINETIC PARAMETERS; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; ANIMAL; DIETARY SUPPLEMENT;

ANIMALS; CLINICAL TRIALS AS TOPIC; DIETARY SUPPLEMENTS; HEART FAILURE; HUMANS; UBIQUINONE;

EID: 84978881315     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/j.pharep.2016.05.012     Document Type: Review

References (69)

1. [1] Prakash, S., Sunitha, J., Hans, M., Role of coenzyme Q(10) as an antioxidant and bioenergizer in periodontal diseases. Indian J Pharmacol 42:6 (2010), 334–337.
2. [2] Potgieter, M., Pretorius, E., Pepper, M.S., Primary and secondary coenzyme Q10 deficiency: the role of therapeutic supplementation. Nutr Rev 71:3 (2013), 180–188.
3. [3] Alehagen, U., Johansson, P., Björnstedt, M., Rosén, A., Dahlström, U., Cardiovascular mortality and N-terminal-proBNP reduced after combined selenium and coenzyme Q10 supplementation: a 5-year prospective randomized double-blind placebo-controlled trial among elderly Swedish citizens. Int J Cardiol 167:5 (2013), 1860–1866.
4. [4] Tsuneki, H., Tokai, E., Suzuki, T., Seki, T., Okubo, K., Wada, T., et al. Protective effects of coenzyme Q10 against angiotensin II-induced oxidative stress in human umbilical vein endothelial cells. Eur J Pharmacol 701:1-3 (2013), 218–227.
5. [5] Gvozdjakova, A., Takahashi, T., Singh, R.B., De Meester, F., Wilson, D.W., Crane, F.L., New roles of coenzyme Q10 discovered by a single group. World Heart J 5 (2013), 159–171.
6. [6] Cluis, C.P., Burja, A.M., Martin, V.J., Current prospects for the production of coenzyme Q10 in microbes. Trends Biotechnol 25 (2007), 514–521.
7. [7] Bhagavan, H.N., Chopra, R.K., Coenzyme Q10. Absorption, tissue uptake, metabolism and pharmacokinetics. Free Radic Res 40 (2006), 445–453.
8. [8] Kumar, A., Kaur, H., Devi, P., Mohan, V., Role of coenzyme Q10 (CoQ10) in cardiac disease, hypertension and Meniere-like syndrome. Pharmacol Ther 124 (2009), 259–268.
9. [9] Linnane, A.W., Kopsidas, G., Zhang, C., Yarovaya, N., Kovalenko, S., Papakostopoulos, P., et al. Cellular redox activity of coenzyme Q10: effect of CoQ10 supplementation on human skeletal muscle. Free Radic Res 36:4 (2002), 445–453.
10. [10] Dallner, G., Sindelar, P.J., Regulation of ubiquinone metabolism. Free Radic Biol Med 29:3-4 (2000), 285–294.
11. [11] Littarru, G.P., Tiano, L., Bioenergetic and antioxidant properties of coenzyme Q10: recent developments. Mol Biotechnol 37 (2007), 31–37.
12. [12] Zaki, N.M., Strategies for oral delivery and mitochondrial targeting of CoQ10. Drug Deliv(December), 2014, 1–14 [Epub ahead of print].
13. [13] Hosoe, K., Kitano, M., Kishida, H., Kubo, H., Fujii, K., Kitahara, M., Study on safety and bioavailability of ubiquinol (Kaneka QH™) after single and 4-week multiple oral administration to healthy volunteers. Regul Toxicol Pharmacol 47 (2007), 19–28.
14. [14] Sun, J., Wang, F., Sui, Y., She, Z., Zhai, W., Wang, C., et al. Effect of particle size on solubility, dissolution rate, and oral bioavailability: evaluation using coenzyme Q₁₀ as naked nanocrystals. Int J Nanomedicine 7 (2012), 5733–5744.
15. [15] Zhou, H., Liu, G., Zhang, J., Sun, N., Duan, M., Yan, Z., et al. Novel lipid-free nanoformulation for improving oral bioavailability of coenzyme Q10. Biomed Res Int, 2014, 2014, 793879, 10.1155/2014/793879.Epub2014Jun5.
16. [16] Ozaki, A., Muromachi, A., Sumi, M., Sakai, Y., Morishita, K., Okamoto, T., Emulsification of coenzyme Q10 using gum arabic increases bioavailability in rats and human and improves food-processing suitability. J Nutr Sci Vitaminol 56:1 (2010), 41–47.
17. [17] Weis, M., Mortensen, S.A., Rassing, M.R., Møller-Sonnergaard, J., Poulsen, G., Rasmussen, S.N., Bioavailability of four oral coenzyme Q10 formulations in healthy volunteers. Mol Aspects Med 15 (1994), 273–280.
18. [18] Terao, K., Nakata, D., Fukumi, H., Schmid, G., Arima H,Hirayama F, Uekama K. Enhancement of oral bioavailability of coenzyme Q10 by complexation with γ-cy clodextrin in healthy adults. Nutr Res 26 (2006), 503–508.
19. [19] Schulz, C., Obermüller-Jevic, U.C., Hasselwander, O., Bernhardt, J., Biesalski, H.K., Comparison of the relative bioavailability of different coenzyme Q10formulationswith a novel solubilizate (Solu Q10). Int J Food Sci Nutr 57 (2006), 546–555.
20. [20] Nanjwade, B.K., Kadam, V.T., Manvi, F.V., Formulation and characterization of nanostructured lipid carrier of ubiquinone (Coenzyme Q10). J Biomed Nanotechnol 9:3 (2013), 450–460.
21. [21] Swarnakar, N.K., Jain, A.K., Singh, R.P., Godugu, C., Das, M., Jain, S., Oral bioavailability, therapeutic efficacy and reactive oxygen species scavenging properties of coenzyme Q10-loaded polymeric nanoparticles. Biomaterials 32 (2011), 6860–6874.
22. [22] Bhagavan, H.N., Chopra, R.K., Plasma coenzyme Q10 response to oral ingestion of coenzyme Q10 formulations. Mitochondrion 7 (2007), 78–88.
23. [23] Miles, M.V., The uptake and distribution of coenzyme Q (10). Mitochondrion 7 (2007), 72–77.
24. [24] Tomono, Y., Hasegawa, J., Seki, T., Motegi, K., Morishita, N., Pharmacokinetic study of deuterium-labelled coenzyme Q10 in man. Int J Clin Pharmacol Ther Toxicol 24:10 (1986), 536–541.
25. [25] Folkers, K., Vadhanavikit S,Mortensen S.A. Biochemical rationale and myocardial tissue data on the effective therapy of cardiomyopathy with coenzyme Q10. Proc Natl Acad Sci U S A 82:3 (1985), 901–904.
26. [26] Pepe, S., Marasco, S.F., Haas, S.J., Sheeran, F.L., Krum, H., Rosenfeldt, F.L., Coenzyme Q10 in cardiovascular disease. Mitochondrion(Suppl. 7), 2007, S154–67.
27. [27] Rosenfeldt, F., Marasco, S., Lyon, W., Wowk, M., Sheeran, F., Bailey, M., Esmore, D., Davis, B., Pick, A., Rabinov, M., Smith, J., Nagley, P., Pepe, S., Coenzyme Q10 therapy before cardiac surgery improves mitochondrial function and in vitro contractility of myocardial tissue. J Thorac Cardiovasc Surg 129:1 (2005 Jan), 25–32.
28. [28] Mozaffarian, D., Benjamin, E.J., Go, A.S., Arnett, D.K., Blaha, M.J., Cushman, M., et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee: heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation 133:4 (2016), e38–e360.
29. [29] Gąsiorowski, A., Dutkiewicz, J., Comprehensive rehabilitation in chronic heart failure. Ann Agric Environ Med 20:3 (2013), 606–612.
30. [30] McMurray, J.J., Adamopoulos, S., Anker, S.D., Auricchio, A., Böhm, M., Dickstein, K., et al. ESC Committee for Practice Guidelines: ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 33:14 (2012), 1787–1847.
31. [31] Eilat-Adar, S., Sinai, T., Yosefy, C., Henkin, Y., Nutritional recommendations for cardiovascular disease prevention. Nutrients 5:9 (2013), 3646–3683.
32. [32] Johansson, P., Dahlström, Ö., Dahlström, U., Alehagen, U., Effect of selenium and Q10 on the cardiac biomarker NT-proBNP. Scand Cardiovasc J 47:5 (2013), 281–288.
33. [33] Stocker, R., Macdonald, P., The benefit of coenzyme Q10 supplements in the management of chronic heart failure: a long tale of promise in the continued absence of clear evidence. Am J Clin Nutr 97:2 (2013), 233–234.
34. [34] Lance, J., McCabe, S., Clancy, R.L., Pierce, J., Coenzyme Q10–a therapeutic agent. Medsurg Nurs 21:6 (2012), 367–371.
35. [35] Yamamura, Y., Ishiyama, T., Yamagami, T., Morita, Y., Ishio, S., Kashiwamura, S., et al. Clinical uses of coenzyme −Q for treatment of cardiovascular disease. Jpn Circ J 31 (1967), 168–169.
36. [36] Crane, F.L., Biochemical functions of coenzyme Q10. J Am Coll Nutr 20:6 (2001), 591–598.
37. [37] Kumar, A., Kartikey, N.S., Niaz, M.A., Singh, R.B., Effect of Q gel (coenzyme Q10) in patients with end stage heart failure targetted for heart transplantation. Third Conference of the International Coenzyme Q10 Association, London, UK, 2002.
38. [38] Nakamura, T., Sanma, H., Himeno, M., Kato, K., Transfer of exogenous coenzyme Q10 to the inner membrane of heart mitochondria in rats. Folkers, K., Yamamura, Y., (eds.) Biomedical and clinical aspects of coenzyme Q, vol. 2, 2016, Elsevier/North-Holland Press, 1980, 3–14.
39. [39] Crestanello, J.A., Kamelgard, J., Lingle, D.M., Mortensen, S.A., Rhode, M., Whitman, G.J., Elucidation of a tripartite mechanism underlying the improvement in cardiac tolerance to ischemia by coenzyme Q10 pretreatment. J Thorac Cardiovasc Surg 111:2 (1996), 443–450.
40. [40] Vogt, A.M., Heart failure: is there an energy deficit contributing to contractile dysfunction?. Basic Res Cardiol 93:1 (1998), 1–10.
41. [41] Soja, A.M., Mortensen, S.A., Treatment of congestive heart failure with coenzyme Q10 illuminated by meta-analyses of clinical trials. Mol Aspects Med 18 (1997), 159–168.
42. [42] Sander, S., Coleman, C.I., Patel, A.A., Kluger, J., White, C.M., The impact of coenzyme Q10 on systolic function in patients with chronic heart failure. J Card Fail 12 (2006), 464–472.
43. [43] Fotino, A.D., Thompson-Paul, A.M., Bazzano, L.A., Effect of coenzyme Q10 supplementation on heart failure: a meta-analysis. Am J Clin Nutr 97:2 (2013), 268–275.
44. [44] Baggio, E., Gandini, R., Plancher, A.C., Passeri, M., Carmosino, G., Italian multicenter study on the safety and efficacy of coenzyme Q10 as adjunctive therapy in heart failure. CoQ10 Drug Surveillance Investigators. Mol. Aspects Med 15 (1994), 287–294.
45. [45] Kumar, A., Singh, R.B., Saxena, M., et al. Effects of carni Q-gel (carnitine plus ubiquinol) on cytokines in patients with heart failure in the Tishcon study. Acta Cardiol 62 (2007), 349–354.
46. [46] Dai, Y.L., Luk, T.H., Yiu, K.H., Wang, M., Yip, P.M., Lee, S.W., et al. Reversal of mitochondrial dysfunction by coenzyme Q10 supplement improves endothelial function in patients with ischaemic left ventricular systolic dysfunction: A randomized controlled trial. Atherosclerosis 216 (2011), 395–401.
47. [47] Tiano, L., Belardinelli, R., Carnevali, P., et al. Effect of coenzyme Q10 administration on endothelial function and extracellular superoxide dismutase in patients with ischaemic heart disease: a double-blind, randomized controlled study. Eur Heart J 28 (2007), 2249–2255.
48. [48] Belardinelli, R., Muçaj, A., Lacalaprice, F., Solenghi, M., Seddaiu, G., Principi, F., et al. Coenzyme Q10 and exercise training in chronic heart failure. Eur Heart J 27 (2006), 2675–2681.
49. [49] Hamilton, S.J., Chew, G.T., Watts, G.F., Coenzyme Q10 improves endothelial dysfunction in statin-treated type 2 diabetic patients. Diab Care 32 (2009), 810–812.
50. [50] Shimbo, D., Grahame-Clarke, C., Miyake, Y., Rodriguez, C., Sciacca, R., Di Tullio M, et al: The association between endothelial dysfunction and cardiovascular outcomes in a population-based multi-ethnic cohort. Atherosclerosis 192 (2007), 197–203.
51. [51] Neunteufl, T., Heher, S., Katzenschlager, R., Wölfl, G., Kostner, K., Maurer, G., et al. Late prognostic value of flowmediated dilation in the brachial artery of patients with chest pain. Am J Cardiol 86 (2000), 207–210.
52. [52] Berman, M., Erman, A., Ben-Gal, T., Dvir, D., Georghiou, G.P., Stamler, A., et al. Coenzyme Q10 in Patients with End-Stage Heart Failure Awaiting Cardiac Transplantation: A Randomized, Placebo-Controlled Study. Clin Cardiol 27:5 (2004), 295–299.
53. [53] Langsjoen, P., Lack of effect of coenzyme Q on left ventricular function in patients with congestive heart failure. J Am Coll Cardiol 35 (2000), 816–817.
54. [54] Hofman-Bang, C., Rehnqvist, N., Swedberg, K., Wiklund, I., Aström, H., Coenzyme Q10 as an adjunctive in the treatment of chronic congestive heart failure. The Q10 Study Group. J Card Fail 1:2 (1995), 101–107.
55. [55] Watson, P.S., Scalia, G.M., Galbraith, A., Burstow, D.J., Bett, N., Aroney CN: Lack of effect of coenzyme Q on left ventricular function in patients with congestive heart failure. J Am Coll Cardiol 33:6 (1999), 1549–1552.
56. [56] Khatta, M., Alexander, B.S., Krichten, C.M., Fisher, M.L., Freudenberger, R., Robinson, S.W., Gottlieb, S.S., The effect of coenzyme Q10 in patients with congestive heart failure. Ann Intern Med 132:8 (2000), 636–640.
57. [57] Belardinelli, R., Muçaj, A., Lacalaprice, F., Solenghi, M., Principi, F., Tiano, L., et al. Coenzyme Q10 improves contractility of dysfunctional myocardium in chronic heart failure. Biofactors 25:1-4 (2005), 137–145.
58. [58] Atar, D., Mortensen, S.A., Flachs, H., Herzog, W.R., Coenzyme Q10 protects ischemic myocardium in an open-chest swine model. Clin Investig 71:8 (1993), 103–111.
59. [59] Gvozdjáková, A., Kucharská, J., Mizera, S., Braunová, Z., Schreinerová, Z., Schrameková, E., et al. Coenzyme Q10 depletion and mitochondrial energy disturbances in rejection development in patients after heart transplantation. Biofactors 9:2–4 (1999), 301–306.
60. [60] Kucharská, J., Gvozdjáková, A., Mizera, S., Braunová, Z., Schreinerová, Z., Pechán, I., et al. Participation of coenzyme Q10 in the rejection development of the transplanted heart: A clinical study. Physiol Res 47 (1998), 399–404.
61. [61] Molyneux, S.L., Florkowski, C.M., George, P.M., Pilbrow, A.P., Frampton, C.M., Lever, M., Richards, A.M., Coenzyme Q10: an independent predictor of mortality in chronic heart failure. J Am Coll Cardiol 52:October (18) (2008), 1435–1441.
62. [62] McMurray, J.J., Dunselman, P., Wedel, H., Cleland, J.G., Lindberg, M., Hjalmarson, A., et al. Study Group Coenzyme Q10, rosuvastatin, and clinical outcomes in heart failure: a pre-specified substudy of CORONA (controlled rosuvastatin multinational study in heart failure). J Am Coll Cardiol 56:15 (2010), 1196–2004.
63. [63] Mortensen, S.A., Overview on coenzyme Q10 as adjunctive therapy in chronic heart failure Rationale, design and end-points of Q-symbio – A multinational trial. Biofactors 18 (2003), 79–89.
64. [64] Mortensen, S.A., Rosenfeldt, F., Kumar, A., Dolliner, P., Filipiak, K.J., Pella, D., et al. Q-SYMBIO Study Investigators: The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure. Results from the Q-SYMBIO: a randomized double-blind study. JACC Heart Fail 2:6 (2014), 641–649.
65. [65] Rosenfeldt, F.L., Haas, S.J., Krum, H., Hadj, A., Ng, K., Leong, J.Y., et al. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. J Hum Hypertens 21:4 (2007), 297–306.
66. [66] Yancy, C.W., Jessup, M., Bozkurt, B., Butler, J., Casey, D.E. Jr, Drazner, M.H., et al. American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62:16 (2013), 147–239.
67. [67] Chopra, R.K., Goldman, R., Sinatra, S.T., Bhagavan, H.N., Relative bioavailability of coenzyme Q10 formulations in human subjects. Int J Vitam Nutr Res 68:2 (1998), 109–113.
68. [68] Zita, C., Overvad, K., Mortensen, S.A., Sindberg, C.D., Moesgaard, S., Hunter, D.A., Serum coenzyme Q10 concentrations in healthy men supplemented with 30 mg or 100 mg coenzyme Q10 for two months in a randomised controlled study. Biofactors 18:1–4 (2003), 185–193.
69. [69] Rosenfeldt, F., Marasco, S., Lyon, W., Wowk, M., Sheeran, F., Bailey, M., et al. Coenzyme Q10 therapy before cardiac surgery improves mitochondrial function and in vitro contractility of myocardial tissue. J Thorac Cardiovasc Surg 129:1 (2005), 25–32.